You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Prevention and Treatment of Papillomavirus-Related Cancers Through Immunization
|
|---|---|
| Published in |
Annual Review of Immunology, April 2011
|
| DOI | 10.1146/annurev-immunol-031210-101308 |
| Pubmed ID | |
| Authors |
Ian H. Frazer, Graham R. Leggatt, Stephen R. Mattarollo |
| Abstract |
Cervical and other anogenital cancers are initiated by infection with one of a small group of human papillomaviruses (HPV). Virus-like particle-based vaccines have recently been developed to prevent infection with two cancer-associated HPV genotypes (HPV16, HPV18) and have been ∼95% effective at preventing HPV-associated disease caused by these genotypes in virus-naive subjects. Although immunization induces virus-neutralizing antibody sufficient to prevent infection, persistence of antibody as measured by current assays does not appear necessary to maintain protection over time. Investigators have not identified a reliable surrogate immunological marker of protection against disease following immunization. The prophylactic vaccines are not therapeutic for existing infection. Trials of HPV-specific immunotherapy have shown some efficacy for existing disease, although animal modeling suggests that a combination of immunization and local enhancement of innate immunity may be necessary for optimal therapeutic outcome. HPV prophylactic vaccines are the first vaccines designed to prevent a human cancer and are the practical outcome of a global collaborative effort between basic and applied scientists, clinicians, and industry. |
Mendeley readers
The data shown below were compiled from readership statistics for 109 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 1 | <1% |
| Australia | 1 | <1% |
| Brazil | 1 | <1% |
| Sweden | 1 | <1% |
| Mexico | 1 | <1% |
| Thailand | 1 | <1% |
| Unknown | 103 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 22 | 20% |
| Researcher | 17 | 16% |
| Student > Master | 14 | 13% |
| Student > Bachelor | 13 | 12% |
| Student > Doctoral Student | 7 | 6% |
| Other | 19 | 17% |
| Unknown | 17 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 32 | 29% |
| Agricultural and Biological Sciences | 31 | 28% |
| Biochemistry, Genetics and Molecular Biology | 10 | 9% |
| Immunology and Microbiology | 8 | 7% |
| Engineering | 2 | 2% |
| Other | 6 | 6% |
| Unknown | 20 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 March 2011.
All research outputs
#20,142,242
of 22,647,730 outputs
Outputs from Annual Review of Immunology
#894
of 905 outputs
Outputs of similar age
#102,193
of 109,250 outputs
Outputs of similar age from Annual Review of Immunology
#19
of 19 outputs
Altmetric has tracked 22,647,730 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 905 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.1. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 109,250 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.